WO2012139081A3 - Méthodes de traitement d'états associés à une activation du complément dépendant de masp-2 - Google Patents

Méthodes de traitement d'états associés à une activation du complément dépendant de masp-2 Download PDF

Info

Publication number
WO2012139081A3
WO2012139081A3 PCT/US2012/032650 US2012032650W WO2012139081A3 WO 2012139081 A3 WO2012139081 A3 WO 2012139081A3 US 2012032650 W US2012032650 W US 2012032650W WO 2012139081 A3 WO2012139081 A3 WO 2012139081A3
Authority
WO
WIPO (PCT)
Prior art keywords
masp
complement activation
dependent complement
methods
dependent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/032650
Other languages
English (en)
Other versions
WO2012139081A2 (fr
Inventor
Gregory A. Demopulos
Tom DUDLER
Hans-Wilhelm Schwaeble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leicester
Omeros Corp
Original Assignee
University of Leicester
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2832187A priority Critical patent/CA2832187C/fr
Priority to PL17191208T priority patent/PL3287142T3/pl
Priority to KR1020187017317A priority patent/KR20180072851A/ko
Priority to NZ617298A priority patent/NZ617298A/en
Priority to EP17191208.2A priority patent/EP3287142B1/fr
Priority to KR1020227010108A priority patent/KR20220044616A/ko
Priority to KR1020197037437A priority patent/KR102217658B1/ko
Priority to EP21188935.7A priority patent/EP3964233A1/fr
Priority to AU2012239889A priority patent/AU2012239889B2/en
Priority to BR112013025917A priority patent/BR112013025917A2/pt
Priority to KR1020217004368A priority patent/KR20210021101A/ko
Priority to CN201280028263.2A priority patent/CN103781492A/zh
Priority to KR1020177007747A priority patent/KR101870915B1/ko
Priority to EP12767899.3A priority patent/EP2694108B1/fr
Priority to MX2013011721A priority patent/MX339002B/es
Application filed by University of Leicester, Omeros Medical Systems Inc filed Critical University of Leicester
Priority to KR1020137029501A priority patent/KR101720562B1/ko
Priority to ES12767899T priority patent/ES2683307T3/es
Priority to DK12767899.3T priority patent/DK2694108T3/en
Priority to JP2014504058A priority patent/JP5937197B2/ja
Priority to MX2018005314A priority patent/MX381987B/es
Priority to RU2013149792A priority patent/RU2662563C2/ru
Priority to MX2016006039A priority patent/MX355648B/es
Publication of WO2012139081A2 publication Critical patent/WO2012139081A2/fr
Publication of WO2012139081A3 publication Critical patent/WO2012139081A3/fr
Priority to IL228758A priority patent/IL228758B/en
Anticipated expiration legal-status Critical
Priority to IL264172A priority patent/IL264172B/en
Priority to IL274206A priority patent/IL274206A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)

Abstract

Dans un aspect, l'invention concerne des procédés d'inhibition des effets de l'activation du complément dépendant de MASP-2 dans un sujet vivant. Les procédés comprennent l'étape d'administration, à un sujet en ayant besoin, d'une quantité d'un agent inhibiteur de MASP-2 efficace pour inhiber l'activation du complément dépendant de MASP-2. Dans certains modes de réalisation, l'agent inhibiteur de MASP-2 inhibe une lésion cellulaire associée à une activation de la voie alternative du complément à médiation par MASP-2, tout en laissant intact le composant de la voie classique (dépendant de Clq) du système immunitaire. Dans un autre aspect, l'invention concerne des compositions pour l'inhibition des effets de l'activation du complément dépendant de la lectine, comprenant une quantité thérapeutiquement efficace d'un agent inhibiteur de MASP-2 et d'un vecteur pharmaceutiquement acceptable.
PCT/US2012/032650 2011-04-08 2012-04-06 Méthodes de traitement d'états associés à une activation du complément dépendant de masp-2 Ceased WO2012139081A2 (fr)

Priority Applications (25)

Application Number Priority Date Filing Date Title
MX2013011721A MX339002B (es) 2011-04-08 2012-04-06 El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
KR1020187017317A KR20180072851A (ko) 2011-04-08 2012-04-06 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
NZ617298A NZ617298A (en) 2011-04-08 2012-04-06 Methods for treating conditions associated with masp-2 dependent complement activation
EP17191208.2A EP3287142B1 (fr) 2011-04-08 2012-04-06 Méthodes de traitement d'états associés à une activation du complément dépendant de masp-2
KR1020227010108A KR20220044616A (ko) 2011-04-08 2012-04-06 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
KR1020197037437A KR102217658B1 (ko) 2011-04-08 2012-04-06 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
EP21188935.7A EP3964233A1 (fr) 2011-04-08 2012-04-06 Méthodes de traitement d'états associés à une activation du complément dépendant de masp-2
AU2012239889A AU2012239889B2 (en) 2011-04-08 2012-04-06 Methods for treating conditions associated with MASP-2 dependent complement activation
BR112013025917A BR112013025917A2 (pt) 2011-04-08 2012-04-06 uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
KR1020217004368A KR20210021101A (ko) 2011-04-08 2012-04-06 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
CN201280028263.2A CN103781492A (zh) 2011-04-08 2012-04-06 用于治疗与masp-2依赖性补体活化相关的状况的方法
KR1020177007747A KR101870915B1 (ko) 2011-04-08 2012-04-06 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
EP12767899.3A EP2694108B1 (fr) 2011-04-08 2012-04-06 Méthodes de traitement d'états associés à une activation du complément dépendant de masp-2
CA2832187A CA2832187C (fr) 2011-04-08 2012-04-06 Methodes de traitement d'etats associes a une activation du complement dependant de masp-2
MX2018005314A MX381987B (es) 2011-04-08 2012-04-06 El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2
MX2016006039A MX355648B (es) 2011-04-08 2012-04-06 El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
ES12767899T ES2683307T3 (es) 2011-04-08 2012-04-06 Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2
DK12767899.3T DK2694108T3 (en) 2011-04-08 2012-04-06 METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
JP2014504058A JP5937197B2 (ja) 2011-04-08 2012-04-06 Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
PL17191208T PL3287142T3 (pl) 2011-04-08 2012-04-06 Sposoby leczenia chorób związanych z aktywacją dopełniacza zależną od masp-2
RU2013149792A RU2662563C2 (ru) 2011-04-08 2012-04-06 Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента
KR1020137029501A KR101720562B1 (ko) 2011-04-08 2012-04-06 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
IL228758A IL228758B (en) 2011-04-08 2013-10-06 Masp-2 inhibiting agent for use in treating paroxysmal nocturnal hemoglobinuria
IL264172A IL264172B (en) 2011-04-08 2019-01-09 Masp-2 inhibitory agents for use in treating atypical hemolytic uremic syndrome (ahus)
IL274206A IL274206A (en) 2011-04-08 2020-04-23 MASP-2 suppressors for use in the treatment of radiation heredity syndrome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161473698P 2011-04-08 2011-04-08
US61/473,698 2011-04-08

Publications (2)

Publication Number Publication Date
WO2012139081A2 WO2012139081A2 (fr) 2012-10-11
WO2012139081A3 true WO2012139081A3 (fr) 2012-11-29

Family

ID=46966283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/032650 Ceased WO2012139081A2 (fr) 2011-04-08 2012-04-06 Méthodes de traitement d'états associés à une activation du complément dépendant de masp-2

Country Status (17)

Country Link
US (6) US8951522B2 (fr)
EP (3) EP2694108B1 (fr)
JP (4) JP5937197B2 (fr)
KR (6) KR102217658B1 (fr)
CN (3) CN110075294A (fr)
AU (1) AU2012239889B2 (fr)
BR (1) BR112013025917A2 (fr)
CA (4) CA3237802A1 (fr)
CL (1) CL2013002874A1 (fr)
DK (2) DK2694108T3 (fr)
ES (2) ES2683307T3 (fr)
IL (3) IL228758B (fr)
MX (3) MX339002B (fr)
NZ (5) NZ617298A (fr)
PL (1) PL3287142T3 (fr)
RU (2) RU2743409C2 (fr)
WO (1) WO2012139081A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535650B1 (en) 2014-06-12 2022-12-27 Ra Pharmaceuticals, Inc. Modulation of complement activity
US11939577B2 (en) 2018-09-25 2024-03-26 Centre National De La Recherche Scientifique Antisense RNA targeting PMP22 for the treatment of Charcot-Marie-Tooth 1A disease
US12239684B2 (en) 2015-01-28 2025-03-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
US12558398B2 (en) 2019-06-04 2026-02-24 Ucb Holdings, Inc. Inflammatory disease treatment with complement inhibitors

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0688182B2 (ja) 1986-09-08 1994-11-09 バブコツク日立株式会社 スタツド着脱装置
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
SG10201703249PA (en) * 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
NZ629675A (en) * 2012-04-06 2017-02-24 Omeros Corp Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
PT2861246T (pt) * 2012-06-18 2021-04-05 Univ Leicester Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
WO2014066744A2 (fr) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anticorps de la c1s anti-complément et leurs utilisations
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
CA2906096C (fr) * 2013-03-15 2022-03-15 Omeros Corporation Methodes de generation d'anticorps porteurs de peptide bioactif et compositions les comprenant
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
RS61351B1 (sr) * 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
WO2015070041A1 (fr) * 2013-11-08 2015-05-14 Icahn School Of Medicine At Mount Sinai Procédés de surveillance d'un dysfonctionnement rénal
EP4212175A1 (fr) 2015-04-06 2023-07-19 Bioverativ USA Inc. Anticorps anti-c1s humanisés et leurs procédés d'utilisation
CN117398458A (zh) 2015-11-09 2024-01-16 奥默罗斯公司 用于治疗与masp-2依赖性补体活化相关的病况的方法
KR20260070290A (ko) 2015-12-16 2026-05-18 유씨비 홀딩스 인코포레이티드 보체 활성의 조절인자
LT3394089T (lt) * 2015-12-23 2021-11-25 eleva GmbH Polipeptidai, skirti komplemento aktyvacijos inhibicijai
CA3010593C (fr) * 2016-01-05 2024-02-13 University Of Leicester Methodes d'inhibition d'une fibrose chez un sujet ayant besoin d'un tel traitement
NZ745531A (en) 2016-03-31 2020-09-25 Omeros Corp Methods for inhibiting angiogenesis in a subject in need thereof
UY37376A (es) * 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
IL326479A (en) 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
AU2017342428B2 (en) * 2016-10-13 2021-02-04 Omeros Corporation Methods for reducing proteinuria in a human subject suffering from immunoglobulin a Nephropathy
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
JP6442703B2 (ja) * 2016-12-26 2018-12-26 日本ビーシージー製造株式会社 細菌細胞壁骨格成分を含有する水中油型エマルション製剤
KR20190128674A (ko) * 2017-03-09 2019-11-18 쿄와 기린 가부시키가이샤 Masp2의 발현을 억제하는 핵산
US20210093654A1 (en) * 2017-07-28 2021-04-01 Lemonex Inc. Pharmaceutical composition for preventing or treating liver cancer
JP7360716B2 (ja) 2017-12-01 2023-10-13 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
HRP20250277T1 (hr) 2017-12-01 2025-05-09 Suzhou Ribo Life Science Co., Ltd. Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
WO2019105414A1 (fr) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 Acide nucléique, composition et conjugué contenant un acide nucléique, procédé de préparation et utilisation associés
CN118291456A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
BR112020010916A2 (pt) 2017-12-04 2020-11-17 Ra Pharmaceuticals, Inc moduladores da atividade do complemento
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2019231935A1 (fr) 2018-05-29 2019-12-05 Omeros Corporation Inhibiteurs de masp-2 et procédés d'utilisation
RU2699040C1 (ru) * 2018-07-23 2019-09-03 Федеральное государственное бюджетное учреждение науки "Уральский научно-практический центр радиационной медицины Федерального медико-биологического агентства" (ФГБУН УНПЦ РМ ФМБА России) Способ экстренной профилактики и лечения острой лучевой болезни (варианты)
WO2020038377A1 (fr) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 Acide nucléique, composition et conjugué contenant un acide nucléique et leur procédé d'utilisation
JP7376952B2 (ja) 2018-09-30 2023-11-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド ｓｉＲＮＡ複合体及びその調製方法と使用
MX2021005758A (es) * 2018-11-15 2021-09-21 Ionis Pharmaceuticals Inc Moduladores de la expresión de irf5.
CA3124730A1 (fr) * 2018-12-25 2020-07-02 Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences Petit medicament a base d'arn pour la prevention et le traitement de maladies liees a une l'inflammation et leur combinaison
JP7507495B2 (ja) 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
JP2022524078A (ja) 2019-03-08 2022-04-27 ラ ファーマシューティカルズ インコーポレイテッド 深部組織浸透性ｃ５阻害剤としてのジルコプラン
EP3981431A4 (fr) * 2019-03-14 2023-06-28 Rena Therapeutics Inc. Complexe d'acide nucléique pour moduler l'expression d'ihh
JP2022527508A (ja) 2019-03-29 2022-06-02 ラ ファーマシューティカルズ インコーポレイテッド 補体モジュレータ及び関連方法
CN113710230A (zh) 2019-04-24 2021-11-26 Ra制药公司 用于调节补体活性的组合物和方法
CN113227376B (zh) 2019-05-22 2024-04-09 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN113286888B (zh) 2019-05-22 2023-12-22 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
JP7610848B2 (ja) 2019-05-22 2025-01-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
CN113614230B (zh) * 2019-05-22 2024-04-09 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN113795582B (zh) 2019-05-24 2024-05-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN111024947A (zh) * 2019-11-19 2020-04-17 江苏美克医学技术有限公司 白色念珠菌荧光免疫层析测定试剂盒及其制备方法
EP4050957B1 (fr) 2019-11-27 2024-03-06 Kyocera Corporation Procédé et appareil pour éviter des collisions de radiomessagerie dans un équipement utilisateur à multiples cartes sim
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
JP7699389B2 (ja) 2019-12-04 2025-06-27 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
CN115052862A (zh) 2019-12-04 2022-09-13 奥默罗斯公司 Masp-2抑制剂和使用方法
AU2020395306B2 (en) 2019-12-04 2025-04-24 Omeros Corporation MASP-2 inhibitors and methods of use
EP4107165A4 (fr) * 2020-02-19 2025-05-21 Alnylam Pharmaceuticals, Inc. Compositions d'arni de la sérine peptidase 2 de lectine de liaison au mannane (masp2) et leurs procédés d'utilisation
KR102314642B1 (ko) * 2020-04-17 2021-10-20 재단법인 아산사회복지재단 파브리 병 진단용 바이오 마커 및 이의 용도
CN115667925A (zh) * 2020-05-15 2023-01-31 阿雷克森制药公司 使用细胞外囊泡来检测补体激活的方法以及其用于评估和/或监测补体介导的疾病的治疗的用途
CN113674860B (zh) * 2020-05-15 2024-05-17 北京大学人民医院 一种难治性iTTP风险预测装置、系统及其应用
WO2021257480A2 (fr) 2020-06-14 2021-12-23 Catalyst Biosciences, Inc. Compositions et procédés associés au facteur i du complément
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
CN120173119B (zh) * 2020-12-16 2025-09-30 康诺亚生物医药科技（成都）有限公司 一种补体抑制剂的开发和应用
WO2022228364A1 (fr) * 2021-04-25 2022-11-03 江苏恒瑞医药股份有限公司 Anticorps anti-masp2, fragment de liaison à l'antigène de celui-ci et utilisation médicale associée
CA3240483A1 (fr) 2021-12-10 2023-06-15 Thomas Dudler Anticorps therapeutiques qui se lient au domaine serine protease de masp-2 et leurs utilisations
MA71249A (fr) 2022-06-24 2025-04-30 Bioverativ Usa Inc. Méthodes de traitement de maladies médiées par complément
CA3262515A1 (fr) * 2022-07-25 2024-02-01 Amgen Inc. Constructions d'arni et méthodes d'inhibition de l'expression de fam13a
JP2025541737A (ja) 2022-11-30 2025-12-23 オメロス コーポレーション Ｍａｓｐ－２阻害物質としての縮合ピリミジン
US20250122225A1 (en) 2023-10-06 2025-04-17 Omeros Corporation Masp-2 inhibitors and methods of use
CN119978131B (zh) * 2025-04-15 2025-06-27 北京赛斯维德生物科技有限公司 一种血管性血友病因子裂解蛋白酶(adamts13)单克隆抗体、制备方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050191298A1 (en) * 2004-02-03 2005-09-01 Leonard Bell Method of treating hemolytic disease
US20060240476A1 (en) * 2003-03-17 2006-10-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Construct comprising recognition domain of antibody against von willebrand factor-specific cleaving enzyme
US20070015703A1 (en) * 2005-06-17 2007-01-18 Denisa Wagner ADAMTS13-containing compositions having thrombolytic activity
US20110002931A1 (en) * 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
US20110020337A1 (en) * 2004-06-10 2011-01-27 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69030172T2 (de) 1990-01-26 1997-06-19 Immunomedics Inc Impfstoffe gegen Krebs und Infektionskrankheiten
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
JPH07238100A (ja) 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
JP2002532079A (ja) 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
CN1402642A (zh) 1999-07-21 2003-03-12 奥默罗斯公司 用于抑制疼痛,炎症和软骨退化的溶液及方法
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
RU2002113381A (ru) 1999-12-02 2004-01-27 Дженс Христиан ДЖЕНСЕНИУС (DK) MASP-3, комплемент-связывающий фермент и его применение
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
JP5226169B2 (ja) 2000-07-13 2013-07-03 ヘリオン バイオテック アンパーツゼルスカブ Ｍａｓｐ−２、すなわち補体固定酵素及びその使用
EP1416962A4 (fr) 2001-07-26 2006-05-24 Alexion Pharma Inc Procede d'amelioration de la fonction cognitive
MXPA04007124A (es) 2002-02-01 2004-10-29 Omeros Corp Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
AU2003223288A1 (en) 2002-03-18 2003-10-08 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
EP1531757B1 (fr) 2002-07-19 2016-09-07 Omeros Corporation Copolymeres triblocs biodegradables, procedes de synthese, et hydrogels et biomateriaux fabriques a partir de ces derniers
ES2397574T3 (es) 2002-07-30 2013-03-08 Omeros Corporation Procedimiento y soluciones de irrigación oftalmológica
ITRM20020511A1 (it) * 2002-10-09 2004-04-10 Santa Anna Acuto Uso dell'insulator sns di riccio di mare per la terapia genica di malattie delle cellule eritroidi.
EP1570075A2 (fr) 2002-12-03 2005-09-07 Aarhus Universitet Technique de determination de predisposition a une manifestation de maladies associees au systeme immunitaire
AU2004216176B2 (en) 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
HUE034760T2 (en) 2003-05-12 2018-02-28 Helion Biotech Aps Masp-2-T binding antibodies
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2465534B1 (fr) 2004-06-10 2017-03-29 Omeros Corporation Procédés pour le traitement d'états pathologiques liés à l'activation du complément MASP-2 dépendant
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
EP1987354B1 (fr) 2006-01-27 2010-11-03 Rappaport Family Institute for Research in the Medical Sciences Procédés pour évaluer la coagulation sanguine
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
JP6223659B2 (ja) * 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
CA2767755C (fr) 2009-07-17 2021-10-12 Rigshospitalet Inhibiteurs de l'activation du complement
EP3150635A3 (fr) 2009-10-16 2017-06-21 Omeros Corporation Procédés de traitement de la coagulation intravasculaire disséminée par inhibition de l'activation du complément masp-2 dépendant
CN102958535A (zh) * 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
WO2011109338A1 (fr) 2010-03-01 2011-09-09 Alexion Pharmaceuticals Inc. Méthodes et compositions pour le traitement de la maladie de degos
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20150166676A1 (en) 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
HUE049154T2 (hu) 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
PT2861246T (pt) 2012-06-18 2021-04-05 Univ Leicester Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
RS61351B1 (sr) 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
CN117398458A (zh) 2015-11-09 2024-01-16 奥默罗斯公司 用于治疗与masp-2依赖性补体活化相关的病况的方法
NZ745531A (en) * 2016-03-31 2020-09-25 Omeros Corp Methods for inhibiting angiogenesis in a subject in need thereof
JPWO2018070521A1 (ja) * 2016-10-14 2019-08-15 公立大学法人福島県立医科大学 補体の活性化経路を阻害する融合ポリペプチド

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240476A1 (en) * 2003-03-17 2006-10-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Construct comprising recognition domain of antibody against von willebrand factor-specific cleaving enzyme
US20050191298A1 (en) * 2004-02-03 2005-09-01 Leonard Bell Method of treating hemolytic disease
US20110020337A1 (en) * 2004-06-10 2011-01-27 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20070015703A1 (en) * 2005-06-17 2007-01-18 Denisa Wagner ADAMTS13-containing compositions having thrombolytic activity
US20110002931A1 (en) * 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TAYLOR ET AL.: "Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome", PEDIATR. NEPHROL., vol. 23, no. 9, 2008, pages 1425 - 1431, XP019631986 *
WAGNER ET AL.: "'Therapeutic potential of complement modulation", NATURE REVIEWS, vol. 9, no. 1, 2010, pages 43 - 56, XP055085419 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535650B1 (en) 2014-06-12 2022-12-27 Ra Pharmaceuticals, Inc. Modulation of complement activity
US12239684B2 (en) 2015-01-28 2025-03-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11939577B2 (en) 2018-09-25 2024-03-26 Centre National De La Recherche Scientifique Antisense RNA targeting PMP22 for the treatment of Charcot-Marie-Tooth 1A disease
US12558398B2 (en) 2019-06-04 2026-02-24 Ucb Holdings, Inc. Inflammatory disease treatment with complement inhibitors

Also Published As

Publication number Publication date
NZ709997A (en) 2016-03-31
RU2743409C2 (ru) 2021-02-18
CN107638565B (zh) 2021-12-21
US20170166658A1 (en) 2017-06-15
JP6893539B2 (ja) 2021-06-23
KR20140009472A (ko) 2014-01-22
JP2014512363A (ja) 2014-05-22
CL2013002874A1 (es) 2014-03-07
JP2018024698A (ja) 2018-02-15
US20150239985A1 (en) 2015-08-27
CA3076975C (fr) 2024-06-18
MX2013011721A (es) 2014-03-05
DK3287142T3 (da) 2021-11-01
DK2694108T3 (en) 2018-08-20
EP2694108B1 (fr) 2018-06-06
JP2019214616A (ja) 2019-12-19
US20260062498A1 (en) 2026-03-05
EP3287142B1 (fr) 2021-08-04
MX381987B (es) 2025-03-13
CA2977009A1 (fr) 2012-10-11
JP5937197B2 (ja) 2016-06-22
IL264172A (en) 2019-02-28
US8951522B2 (en) 2015-02-10
KR20220044616A (ko) 2022-04-08
CA3237802A1 (fr) 2012-10-11
EP2694108A2 (fr) 2014-02-12
US10202465B2 (en) 2019-02-12
CA3076975A1 (fr) 2012-10-11
RU2018125514A3 (fr) 2019-10-30
NZ617298A (en) 2015-08-28
IL274206A (en) 2020-06-30
AU2012239889A1 (en) 2013-03-14
WO2012139081A2 (fr) 2012-10-11
CN103781492A (zh) 2014-05-07
US20120258095A1 (en) 2012-10-11
KR20190142445A (ko) 2019-12-26
EP3287142A1 (fr) 2018-02-28
AU2012239889B2 (en) 2015-09-03
RU2018125514A (ru) 2019-03-12
KR101870915B1 (ko) 2018-06-25
NZ731596A (en) 2022-07-01
CA2977009C (fr) 2020-05-05
IL228758B (en) 2019-12-31
US20190292272A1 (en) 2019-09-26
CN110075294A (zh) 2019-08-02
KR102217658B1 (ko) 2021-02-22
EP3964233A1 (fr) 2022-03-09
BR112013025917A2 (pt) 2016-12-20
KR20180072851A (ko) 2018-06-29
IL264172B (en) 2022-04-01
US20220089781A1 (en) 2022-03-24
EP2694108A4 (fr) 2014-10-01
MX355648B (es) 2018-04-26
KR20170034941A (ko) 2017-03-29
JP2016185966A (ja) 2016-10-27
ES2683307T3 (es) 2018-09-26
MX339002B (es) 2016-05-06
RU2013149792A (ru) 2015-05-20
ES2894342T3 (es) 2022-02-14
RU2662563C2 (ru) 2018-07-26
PL3287142T3 (pl) 2021-12-27
NZ717517A (en) 2017-07-28
IL228758A0 (en) 2013-12-31
JP6239030B2 (ja) 2017-11-29
CA2832187A1 (fr) 2012-10-11
KR20210021101A (ko) 2021-02-24
CN107638565A (zh) 2018-01-30
CA2832187C (fr) 2017-10-10
NZ746139A (en) 2023-11-24
HK1250342A1 (zh) 2018-12-14
JP6584476B2 (ja) 2019-10-02
KR101720562B1 (ko) 2017-03-30

Similar Documents

Publication Publication Date Title
MX381987B (es) El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2
MX354028B (es) Uso de una composición que comprende un agente inhibidor de masp-2 efectivo para inhibir o prevenir la aparición de agregados en la vasculatura de un sujeto que sufre de un desorden de coagulación mediado por complemento.
WO2007117996A3 (fr) Procédés destinés à traiter des troubles associés à l'activation du complément dépendante de masp-2
WO2005123128A3 (fr) Procedes de traitement d'etats pathologiques associes a l'activation du complement dependante de masp-2
MX2021008044A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
WO2013180834A3 (fr) Compositions et procédés d'inhibition de masp-1 et/ou masp-3 pour le traitement l'hémoglobinurie paroxysmique nocturne
WO2012078633A8 (fr) Méthodes d'inhibition de la métastase d'un cancer
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
HK1258275A1 (zh) 用於调节血管紧张素原表达的化合物和方法
HK1258650A1 (zh) 皮下、舌下和口服治疗用空间稳定载体、用於治疗哺乳动物的组合物和方法
WO2013024282A3 (fr) Composés et leurs utilisations
HK1226063A1 (zh) 选择性grp94抑制剂和其用途
NZ742987A (en) Methods for treating conditions associated with masp-2 dependent complement activation
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
WO2012170947A3 (fr) Procédés pour moduler l'expression du facteur 12
HK1210953A1 (en) Methods for treatment of atherosclerosis
WO2012158672A3 (fr) Composés utilisés dans le traitement de la mucosite
WO2012170945A3 (fr) Procédés pour moduler l'expression de la kallicréine (klkb1)
HK1218251A1 (zh) 用拉喹莫德治疗多发性硬化症
WO2015126930A3 (fr) Pharmacothérapie à effet "booster" pour lutter contre les infections à mycobacterium
WO2014186623A3 (fr) Méthodes et compositions pour le traitement de la maladie de chagas
WO2011153458A3 (fr) Compositions et méthodes utilisables en vue de l'inhibition ou du traitement d'une infection par le virus de la dengue
WO2014145126A3 (fr) Méthodes de traitement de la dyskinésie et de troubles associés
WO2014153643A8 (fr) Compositions et procédés d'utilisation associés dans le traitement de l'aniridie
WO2012158776A3 (fr) Thérapie d'association pour le traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12767899

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2012239889

Country of ref document: AU

Date of ref document: 20120406

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2832187

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014504058

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013002874

Country of ref document: CL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/011721

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2012767899

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20137029501

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IDW00201305163

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 2013149792

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013025917

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013025917

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20131007